Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo ...Middle East

PR Newswire - News
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties Collaboration based on synergies between Adcendo and...

Read More Details
Finally We wish PressBee provided you with enough information of ( Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo )

Apple Storegoogle play

Also on site :



Latest News